PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVoriconazole
Vfend(voriconazole)
Vfend, Voriconazole (voriconazole) is a small molecule pharmaceutical. Voriconazole was first approved as Vfend on 2002-03-19. It is used to treat aspergillosis, candidiasis, fusariosis, and mycoses in the USA. It has been approved in Europe to treat aspergillosis, bacterial infections and mycoses, candidiasis, and mycoses.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Vfend, Voriconazole (discontinued: Voriconazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Voriconazole
Tradename
Company
Number
Date
Products
VORICONAZOLEHikma PharmaceuticalsN-208562 RX2017-03-09
1 products
VFENDCV SciencesN-021266 RX2002-05-24
2 products, RLD, RS
VFENDCV SciencesN-021267 RX2002-05-24
1 products, RLD, RS
VFENDCV SciencesN-021630 RX2003-12-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vfendNew Drug Application2025-03-28
vfenderOTC monograph not final2020-05-30
vfender hand sanitizer gelOTC monograph not final2020-09-01
voriconazoleANDA2025-05-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mycoses—D009181B35-B49
candidiasis—D002177B37
aspergillosisEFO_0007157D001228B44
fusariosisEFO_1001795D060585—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AC: Triazole and tetrazole derivatives
— J02AC03: Voriconazole
HCPCS
Code
Description
J3465
Injection, voriconazole, 10 mg
Clinical
Clinical Trials
198 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B491235819
InfectionsD007239EFO_0000544——213410
AspergillosisD001228EFO_0007157B44—243—8
CandidiasisD002177—B37—133—7
CandidemiaD058387EFO_1001282——123—6
Invasive fungal infectionsD000072742————1225
Communicable diseasesD003141————1225
Invasive candidiasisD058365EFO_1001283B37——12—3
Healthy volunteers/patients———1——1—2
Invasive hydatidiform moleD002820—D39.2——11—2
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive pulmonary aspergillosisD055744—B44.0——2——2
Pulmonary aspergillosisD055732EFO_1001834——12——2
NeuroaspergillosisD020953EFO_0007393———1——1
LeukemiaD007938—C95——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599———1———1
NeutropeniaD009503—D7011———1
Renal insufficiencyD051437—N1911———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249MP_0001845—————11
ScedosporiumD021681——————11
Skin neoplasmsD012878EFO_0004198C44————11
Kidney transplantationD016030——————11
FungemiaD016469—B49————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVoriconazole
INNvoriconazole
Description
Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a member of pyrimidines, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug.
Classification
Small molecule
Drug classsystemic antifungals (miconazole type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
Identifiers
PDB—
CAS-ID137234-62-9
RxCUI—
ChEMBL IDCHEMBL638
ChEBI ID10023
PubChem CID71616
DrugBankDB00582
UNII IDJFU09I87TR (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vfend – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Voriconazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,012 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
20,387 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use